Consistent with a passenger role in prostate cancer cells, among the 202 mCRPC patients in our cohort with long term follow-up data15, presence of FOXA1 3′-UTR alterations did not influence time to progression on first-line abiraterone or enzalutamide therapy (5.6 vs 5.5 months, hazard ratio = 1.03, 95% CI 0.57–1.87, p = 0.92, univariate Cox proportional hazards model) or overall survival from mCRPC treatment initiation (16.6 vs 18.2 months, hazard ratio = 1.46, 95% CI 0.78–2.74, p = 0.24) (Supplementary Fig. 9, Supplementary Data 7). The gene discussed is FOXA1; the disease is prostate carcinoma.